Médecins Sans Frontières released a briefing paper in January 2015 highlighting "serious ethical concerns" over Gilead Sciences' anti-diversion programme for a hepatitis C (HCV) drug.  These concerns relate to the right to health and privacy, and access to medicines.

Business & Human Rights Resource Centre invited Gilead Sciences to respond to the briefing.  The full briefing and the company's response are provided below.